INMB — INmune Bio, Inc.

INmune Bio Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: Approximately $45.9 million for 2025, up from $42.1 million in 2024.
• R&D Expenses: Decreased to approximately $20.7 million in 2025 from $33.2 million in 2024, attributed to lower costs related to the Alzheimer's trial.
• G&A Expenses: Increased to approximately $10.3 million from $9.5 million in 2024.
• Impairment Charge: Recorded a full impairment of $16.5 million on intangible assets following the Phase II results of the Alzheimer's trial.
• Cash Position: As of December 31, 2025, cash and cash equivalents stood at approximately $24.8 million, expected to fund operations through Q1 2027.
• Share Issuance: Raised approximately $27.5 million through common stock offerings during the year.

2. Strategic Updates and Business Highlights

• CORDStrom Program: Advanced towards regulatory submission for Recessive Dystrophic Epidermolysis Bullosa (RDEB). Positive clinical data showed significant wound healing and quality of life improvements. Regulatory submissions planned for the U.K. by mid-summer 2026, followed by the EU and U.S. submissions by the end of 2026.
• XPro Program: Completed the MINDFuL Phase II trial for Alzheimer's disease, showing promising results. The program is preparing for a Phase III trial, with alignment from the FDA on the development path.
• INKmune Program: Completed a Phase II trial in metastatic castration-resistant prostate cancer, meeting primary and two secondary endpoints ahead of schedule and under budget.

3. Forward Guidance and Outlook

• 2026 Focus: Key priorities include advancing CORDStrom towards marketing approval, clarifying the next steps for XPro's Phase IIb trial, and building partnerships and resources for program advancement.
• Regulatory Expectations: Anticipate feedback from regulatory bodies in 2027, with potential approvals for CORDStrom and further clarity on XPro's path.

4. Bad News, Challenges, or Points of Concern

• Alzheimer's Trial Results: The MINDFuL trial did not achieve its top-line primary endpoint, which raises concerns about the program's future and potential marketability.
• Impairment Charge: The significant impairment charge reflects challenges in the Alzheimer's program, potentially impacting investor confidence.
• Regulatory Challenges: Differences in regulatory requirements between the U.K. and U.S. could complicate the submission process for CORDStrom, particularly regarding the use of U.K. donor materials.

5. Notable Q&A Insights

• Regulatory Submission Differences: Management clarified that while the data set for CORDStrom will be consistent across regions, U.S. submissions will require additional testing of U.K. donor materials in U.S. labs.
• Partnership Discussions: Ongoing discussions with potential partners for XPro, with a focus on securing funding and support for the Phase IIb and subsequent registration efforts.
• Market Potential: Management expressed confidence in the attractiveness of the XPro program to both mid-sized and large pharmaceutical companies, given its potential in a large market.

Overall, INmune Bio's 2025 earnings call highlighted significant advancements in its CORDStrom and XPro programs, despite facing challenges with the Alzheimer's trial outcomes and regulatory complexities. The company remains focused on strategic milestones and partnerships to drive future growth.